Verona seen as target for GSK

 H.C. Wainwright says recent comments from GSK's (GSK) commercial head in an interview with the Financial Times and in comments published by The Sunday Times late last week appear to indicate that Verona Pharma (VRNA) could be an attractive takeover target. GSK Chief Commercial Officer Luke Miels indicated that the company would be seeking acquisitions in the $2B range over the next six months to boost its pipeline and Miels highlighted assets in the respiratory and autoimmune disease arenas and indicated that GSK would preferentially focus on single-asset or dual-asset entities, the analyst tells investors.

https://finance.yahoo.com/news/uber-lyft-downgraded-wall-streets-144108349.html